What is the mechanism of atrial fibrillation in thyrotoxicosis?

Mechanism of Atrial Fibrillation in Thyrotoxicosis

Thyrotoxicosis induces atrial fibrillation through multiple electrophysiological mechanisms: shortening of atrial action potential duration and effective refractory periods, increased atrial ectopic activity, elevated left atrial pressure from increased left ventricular mass and impaired ventricular relaxation, and heightened sympathetic tone creating a hyperadrenergic state that promotes both triggered activity and reentry circuits.

Primary Electrophysiological Mechanisms

The development of AF in thyrotoxicosis stems from direct thyroid hormone effects on cardiac electrophysiology through both genomic and non-genomic pathways 1:

Shortened Refractoriness and Action Potential Duration

• Excess thyroid hormone shortens atrial action potential duration (AAPD) and atrial effective refractory period (AERP)
• This creates the substrate for reentry circuits, as AF is more likely when effective refractory periods are short and conduction velocity is altered
• The shortened refractoriness allows for more rapid atrial activation rates and facilitates maintenance of fibrillatory wavelets 1

Increased Ectopic Activity

• Thyroid hormones promote spontaneous firing and triggered activity in pulmonary veins (PVs)
• Enhanced automaticity results from altered intracellular calcium handling and increased delayed afterdepolarizations (DADs)
• The PVs serve as critical triggers for AF initiation in this setting 2, 3

Structural and Hemodynamic Contributors

Atrial Remodeling

• Elevated left atrial pressure develops secondary to:
  • Increased left ventricular mass
  • Impaired ventricular relaxation despite preserved systolic function
  • Increased cardiac output and preload from the hyperdynamic state 1

Ischemic Mechanisms

• Increased resting heart rate creates supply-demand mismatch
• Myocardial oxygen consumption rises while diastolic filling time decreases
• This can produce atrial ischemia that further promotes arrhythmogenesis 1

Neurohormonal Activation

Hyperadrenergic State

• Thyroid hormones potentiate β-adrenergic receptor sensitivity and density
• Increased sympathetic tone accelerates sinus rate and shortens refractoriness
• This elevated catecholamine state is particularly important in acute thyrotoxicosis and thyroid storm 4, 3
• The sympathetic activation explains why beta-blockers are the preferred first-line rate control agents 4, 5

Clinical Context and Risk Factors

AF occurs in 5-15% of hyperthyroid patients overall, but prevalence increases dramatically with age (more common in those >60 years) 4. Recent data confirms approximately 8% prevalence, with independent determinants being older age, male sex, heart failure, and thyroid crisis—notably, thyroid hormone levels themselves were not independently predictive 6.

Critical Point: The presence of underlying structural heart disease (mitral valve prolapse, other valvular disease, cardiomyopathy) accounts for most cases of AF during thyrotoxicosis 7. When no structural disease exists, AF is less common and more likely to spontaneously revert once euthyroid state is restored.

Subclinical Hyperthyroidism

Even subclinical hyperthyroidism (suppressed TSH with normal free T4/T3) carries a 3-fold increased risk of developing AF 1. This suggests that even mild thyroid hormone excess can trigger the electrophysiological changes necessary for AF, particularly in susceptible individuals with other risk factors.

Reversibility

A key distinguishing feature: Antiarrhythmic drugs and cardioversion typically fail to achieve sustained sinus rhythm while thyrotoxicosis persists 4, 5. This underscores that the arrhythmogenic substrate is actively maintained by ongoing thyroid hormone excess. Once euthyroid state is restored, spontaneous reversion to sinus rhythm commonly occurs, particularly in patients without underlying structural heart disease 4, 5, 7.

The mechanism is fundamentally different from primary AF—it represents a reversible, metabolically-driven arrhythmia where correcting the underlying thyroid dysfunction addresses the root electrophysiological abnormalities rather than just suppressing the arrhythmia.